Graves disease marker gene and application thereof

A technology for Graves' disease and marker genes, applied in the field of Graves' disease marker genes and their applications, can solve problems such as difficult differential diagnosis, Parkinson's disease confusion, complexity and time-consuming

Inactive Publication Date: 2022-04-08
杭州拓宏生物科技有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although current diagnostic methods are sufficient for the most severe patients, it is complicated and time-consuming to make a diagnosis based on clinical features and blood indicators, which often delays early diagnosis and treatment for patients with mi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Graves disease marker gene and application thereof
  • Graves disease marker gene and application thereof
  • Graves disease marker gene and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Example 1 Identification of biomarkers

[0074] In this example, the inventors studied the fecal samples of 61 Graves' disease patients and 42 healthy controls to obtain the characteristics of the intestinal flora gene community and functional components. In general, the inventor downloaded about 353.3Gb of high-quality sequencing data (healthy people) and 513.9Gb of high-quality sequencing data obtained from experimental sequencing to construct a reference gene set for Graves' disease. Metagenome analysis showed that 44 genes were closely related to Graves' disease, 41 of which were enriched in the gut genes of healthy people, and 3 genes were enriched in the gut genes of Graves' disease patients.

[0075] 1. Acquisition of sequencing data

[0076] All sample sequencing data were downloaded from literature (PMID: 34079079) from Hainan Provincial People's Hospital, Haikou, China, aged 24-69 years, each subject in the healthy group collected stool samples before the fir...

Embodiment 2

[0102] Verification of embodiment 2 gene markers

[0103]In order to verify the findings in Example 2, the inventors further analyzed the abundance of the 44 genes shown in Table 1 in the feces samples of 20 healthy people and 29 Graves' disease patients in the verification group, and based on the verification situation. The 44 genes were deleted, and the DNA extraction, sequencing and gene abundance analysis of the verified population were performed with reference to Example 1.

[0104] The verification results are as follows: Among the 41 genes enriched in the healthy population, 40 genes were verified with high quality in the verification set (p value <0.02), and the p values ​​of the gene markers enriched in the healthy population in the verification group were The values ​​are shown in Table 2.

[0105] Table 2:

[0106]

[0107]

[0108] For the above-mentioned enrichment in Graves' disease patients, all three genes were verified with high quality in the validati...

Embodiment 3

[0202] The detection of embodiment 3 individual state

[0203] In this example, the inventors used 11 stool samples to detect the individual status of the sample source.

[0204] Determine the gene abundances of GA20_GI_0029955, GA61_GI_0091802, and C02_GI_0042821 shown in Table 3 in each stool sample with reference to the method in Example 2, and determine whether the abundances of these three genes in each sample fall within the respective levels in the disease control group or the healthy control group. The 95% confidence interval of the abundance, it is determined that the abundance of these three genes all fall into the corresponding interval of the disease group, and the individual corresponding to the sample is a Graves' disease patient, and it is determined that the abundance of the three genes all fall into the The status of the individual corresponding to the sample in the corresponding interval of the healthy group is non-Graves' disease patient.

[0205] The resul...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a Graves disease gene marker and application thereof, the Graves disease gene marker comprises a first gene set, the invention further provides a kit, the kit comprises a reagent suitable for detecting at least one gene in the first gene set, the genes in the first gene set are in one-to-one correspondence with nucleotide sequences shown in SEQ ID NO: 1-40, and the nucleotide sequences are shown in SEQ ID NO: 1-40. The genes in the first gene set and the corresponding sequences in SEQ ID NO: 1-40 have no less than 90% of identity. Compared with a Graves disease patient group, the gene provided by the invention is remarkably enriched in healthy individuals, can be used as a distinguishing marker of a healthy group and the Graves disease patient group, and can be used as a marker for detecting and/or treating the Graves disease.

Description

technical field [0001] The present invention relates to the field of biotechnology. Specifically, the present invention relates to Graves' disease marker gene and its application. More specifically, the present invention relates to a kit, the use of the reagent in the preparation of the kit, and the method for preventing or treating Graves' disease. A pharmaceutical composition or a food composition for Graves' disease, a method for determining whether an individual has Graves' disease, a device for determining whether an individual has Graves' disease, a device, and a method for screening drugs. Background technique [0002] Graves' disease (GD, Graves' Disease) refers to toxic diffuse goiter, which is an autoimmune disease that can lead to hyperthyroidism, which means that the human thyroid gland secretes too much thyroid hormone, resulting in a series of symptoms. In areas with sufficient iodine intake, the prevalence of GD is about 0.5%, and the annual incidence rate is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/689C12Q1/02A23L33/00A61K45/00A61P37/02A61P5/14
Inventor 宋瑞雪郑智俊张笑笑
Owner 杭州拓宏生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap